IQVIA Archives -

Market Access/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Innovative Medicines Fund and the opportunity for ICSs-industry collaboration to mobilise NICE approvals

mike.hammerton@pharmaphorum.com IMF, IQVIA, new medicines, NICE, rare disease, Real World Evidence 0 Comment

In June 2022, NHS England (NHSE) and the National Institute for Health and Care Excellence (NICE) launched the

Innovative Medicines Fund and the opportunity for ICSs-industry collaboration to mobilise NICE approvals

https://pharmaphorum.com/views-and-analysis/innovative-medicines-fund-and-the-opportunity-for-icss-industry-collaboration-to-mobilise-nice-approvals/

Market Access/ Views & Analysis/ Views and analysis

Nine for 2023, part three: thriving or surviving?

mike.hammerton@pharmaphorum.com 2023 predictions, competition, financing, HCPs, healthcare, IQVIA, pharma 0 Comment

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that

Nine for 2023, part three: thriving or surviving?

https://pharmaphorum.com/views-and-analysis/nine-for-2023-part-three-thriving-or-surviving/

Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

mike.hammerton@pharmaphorum.com 2023 predictions, ageing, Alzheimer's, diagnostics, IQVIA, pharmacotherapies 0 Comment

The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

https://pharmaphorum.com/views-and-analysis/nine-for-2023-part-two-healthcares-hard-problem-the-prognosis-for-diagnosis-and-key-new-pharmacotherapy-platforms/

Market Access/ Views & Analysis/ Views and analysis

It’s time get real with healthcare’s commitment to net zero

mike.hammerton@pharmaphorum.com COP27, emissions, healthcare, IQVIA, net zero, pharma, Sustainability, United Nations 0 Comment

Every fraction of a degree matters COP27 is in full swing and world leaders are contending with the

It’s time get real with healthcare’s commitment to net zero

https://pharmaphorum.com/views-and-analysis/its-time-get-real-with-healthcares-commitment-to-net-zero/

News/ News/ News/ Patients/ R&D

IQVIA’s report card for clinical trial diversity: must do better

Phil Taylor clinical trials, diversity, IQVIA 0 Comment

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust

IQVIA’s report card for clinical trial diversity: must do better

https://pharmaphorum.com/news/iqvias-report-card-for-clinical-trial-diversity-must-do-better/

IQVIA Webinar on Innovative Medicines Fund

Market Access/ Slider in home page/ Views & Analysis/ Webinars/ Webinars in home page/ Webinars On demand

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

mike.hammerton@pharmaphorum.com Innovative Medicines Fund, IQVIA, NHSE, NICE 0 Comment

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

https://pharmaphorum.com/webinars/innovative-medicines-fund-and-the-opportunity-for-icss-to-mobilise-nice-approvals/

Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Key operational considerations to optimise decentralised clinical trials

mike.hammerton@pharmaphorum.com decentralised clinical trials, IQVIA, patient centricity, patient engagement, patient-centric trials, planning and design, research 0 Comment

Now that the COVID-19 pandemic has provided the industry with a solid foundation of experience with decentralised trials,

Key operational considerations to optimise decentralised clinical trials

https://pharmaphorum.com/views-and-analysis/key-operational-considerations-to-optimise-decentralised-clinical-trials/

R&D/ Views & Analysis/ Views and analysis

How to Successfully Employ External Comparator Arm Studies Using Real World Data

mike.hammerton@pharmaphorum.com analysis, drug approval studies, endpoints, estimands, external comparator arm studies, IQVIA, precision medicine, randomised clinical trials, real world data, single arm trials 0 Comment

Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine

How to Successfully Employ External Comparator Arm Studies Using Real World Data

https://pharmaphorum.com/views-and-analysis/how-to-successfully-employ-external-comparator-arm-studies/

Insights/ Market Access/ Views & Analysis/ Views and analysis

Is the launch environment really more competitive now?

mike.hammerton@pharmaphorum.com competitive intensity, IQVIA, launch environment, market data, pharma, primary care 0 Comment

It’s often stated – mostly without reference to data – that the environment for innovative launches is more

Is the launch environment really more competitive now?

https://pharmaphorum.com/views-and-analysis/is-the-launch-environment-really-more-competitive-now/

Trending

IQVIA

Login